Pentixapharm Holding Ag · XETR:PTP
Pentixapharm — FY2025 Earnings Presentation
27 slides from Pentixapharm's earnings presentation, Mar 26, 2026
Slide 1: Fourth Quarter and FY 2025 Financial Results and Business Update
Fourth Quarter and FY 2025 Financial Results and Business Update Expanding the Boundaries of Radiopharmaceuticals March 26, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements based on the beliefs of Pentixapharm Holding AG management. Such statements reflect current views of Pentixapharm Holding AG with respect to future events and results and are subject to risks and uncertainties. Actual r
Slide 3: Expanding the Boundaries of Radiopharmaceuticals
Expanding the Boundaries of Radiopharmaceuticals Advanced clinical-stage Biotech R&D Model Headquartered in Berlin, Germany Expertise and resources • Novel radiopharmaceuticals More than 30 • Strong clinical development expertise dedicated employees • Solid global regulatory strategy • High-quality
Slide 4: Radiotheranostics: A New Paradigm in Precision Medicine
Radiotheranostics: A New Paradigm in Precision Medicine Radiodiagnostics: High-resolution PET-CT imaging Imaging • Stratify patients for tailored treatment • Map disease distribution at baseline • Track tumor burden with precision Radiotheranostics Seamlessly combining imaging and therapy to improve
Slide 5: Focused Competencies at the Core of the Development Value Chain
Focused Competencies at the Core of the Development Value chain Pentixapharm Core Expertise and Value Drivers Value Inflection Diagnostic IND/ Clinical Clinical In-license Discovery Pre-clinical CTIS Phase 1 Phase 2 Clinical Phase 3 Research & Development combined with Radionuclide Theranostic Appro
Slide 6: Building Pipeline Momentum Across Oncology and Cardiology
Building Pipeline Momentum Across Oncology and Cardiology Lead Pre- IND/ Candidate Target Indication Optimization clinical CTIS Phase I Phase II Phase III Sponsor Radiodiagnostics Hypertension – Primary Aldosteronism PANDA Ph3 ready PentixaFor PT-001 CXCR4 Cardiovascular IITs Hypertension – ⁶⁸Ga End
Slide 7: A Sharper, More Focused Pentixapharm Following Completed Streamlining
A Sharper, More Focused Pentixapharm Following Completed Streamlining Q1 Q2 Q3 Q4 Myelo001 CXCR4 and CD24 Focus on clinical development in Program discontinued following Strategic re-orientation of non-clinical high-value Indications: portfolio prioritization and clinical development Cardiovascular
Slide 8: Pentixapharm FY 2025 Financials & Financial Guidance
Pentixapharm FY 2025 Financials & Financial Guidance March 26, 2026 Pentixapharm・Fourth Quarter and FY 2025 8
Slide 9: Balance Sheet FY 2025
Balance Sheet FY 2025 in € thousands 31.12.2024 31.12.2025 in € thousands 31.12.2024 31.12.2025 Assets Liabilities and Equity Non-current assets Equity Other intangible assets 35.354 32.282 Subscribed capital 24.795 24.795 Property, plant and equipment 269 36 Capital reserves 37.475 38.727 Deferred
Slide 10: Profit & Loss FY 2025
Profit & Loss FY 2025 in € thousands 01-012/2024 01-12/2025 Revenue 118 93 Income from the sale of rights/patents 6.700 0 Other operating income 8.480 543 Cost of materials and external services for research and development -3.718 -6.796 Personnel expenses -1.431 -6.516 Other operating expenses -8.0
Slide 11: Cash Flow Statement FY 2025
Cash Flow Statement FY 2025 in € thousands 01-12/2024 01-12/2025 Prof it/loss -11.927 -16.511 Depreciation, amortization and impairment losses 19.044 3.730 Loss on disposal of fixed assets 0 200 Change in deferred taxes* -4.631 -3.015 Income taxes paid -36 -55 Other non-cash expenses/income -59 1.21
Slide 12: FY 2026 Financial Guidance
FY 2026 Financial Guidance The Company guidance for the full year 2026 is as follows: Total Loss: €21,6 million FY 2026 R&D Personnel & Other Depreciation & Other Interest Expenses: OPEX: non-cash expenses: expenses: €9,7 million €7,4 million €4,1 million €0,4 million 12
Slide 13: Diagnostic and Therapeutic Program Overview
Diagnostic and Therapeutic Program Overview March 26, 2026 Pentixapharm・Fourth Quarter and FY 2025 13
Slide 14: Targeting CXCR4: A Biologically Validated Target
Targeting CXCR4: A Biologically Validated Target From Oncology to Cardiology – CXCR4 Anchors Next-Generation Radiopharmaceuticals CXCR4: One of the most thoroughly researched biological targets of the last decade with a central role in the bone marrow CXCR4 Theranostic in Oncology: CXCR4 Diagnostics
Slide 15: Cardiovascular Program
Cardiovascular Program March 26, 2026 Pentixapharm・Fourth Quarter and FY 2025 15
Slide 16: The Problem: A Massively Underdiagnosed Disease
The Problem: A Massively Underdiagnosed Disease 1.3B 5–10% ~2% People with hypertension Of hypertensives have Screening rate in globally Primary Aldosteronism resistant hypertension AVS The Diagnostic Bottleneck Bottleneck • More than > ~20% prevalence of Primary Aldosteronism in treatment-resistant
Slide 17: Transforming the Diagnostic Pathway in Primary Aldosteronism
Transforming the Diagnostic Pathway in Primary Aldosteronism Subtyping Subtyping Results Therapy Nonlateralizing PA Mineralpocorticoid Adrenal CT/ (mostly BAH) receptor antagonist Adrenal Venous 65% of the cases (Lifelong medication) Sampling (AVS) New Class of Aldosterone Standard of Care Synthase
Slide 18: Transforming the Diagnostic Pathway in Primary Aldosteronism
Transforming the Diagnostic Pathway in Primary Aldosteronism Subtyping Subtyping Results Therapy Nonlateralizing PA Mineralpocorticoid (mostly BAH) receptor antagonist [⁶⁸Ga]GaPentixaFor 65% of the cases (Lifelong medication) PET/CT New Class of Aldosterone Synthase Inhibitors launch expected in H2
Slide 19: The New Hypertension Drug Class Aldosterone Synthase Inhibitor Wave
The New Hypertension Drug Class Aldosterone Synthase Inhibitor Wave: Billions Flowing Into Aldosterone-Driven HTN and Primary Aldosteronism Near-empty: non-oncology The Market Opportunity Cardiovascular & preclinical through Phase 2 P3 Endocrine [68Ga]PentixaFor Primary aldosteronism Anti-HTN Drug M
Slide 20: Oncology Program
Oncology Program March 26, 2026 Pentixapharm・Fourth Quarter and FY 2025 20
Slide 21: Where the Need Is Greatest: Global Incidence of Blood Cancers
Where the Need Is Greatest: Global Incidence of Blood Cancers Requiring Bone Marrow Conditioning Global Incidence cases per year Central Nervous System Lymphoma ~10,000–12,000 Bone Marrow Conditioning & Acute Myeloid Leukemia ~145,000 Treatment Multiple Myeloma ~185,000 March 26, 2026 Pentixapharm・F
Slide 22: Pentilula IIT Phase 1/2 Study of PentixaTher in Relapsed/Refractory AML
Pentilula IIT Phase 1/2 Study of PentixaTher in Relapsed/Refractory Acute Myeloid Leukemia reached highest dose group ! Phase I/II study assessing radioligand therapy with [177Lu]Lu-PentixaTher (PT-002) for relapsed/refractory CXCR4+ acute leukemia Primary Objective: To determine the MTD/DLT of Lu17
Slide 23: Targeting CD24: Highly Specific Cancer Therapy
Targeting CD24: Highly Specific Cancer Therapy From Checkpoint Modulation to Targeted Radiotherapy – CD24 Antibody-Based Radioconjugates CD24: A growing body of translational and early clinical work + positions CD24 as a new therapeutic gateway in oncology and immunology Targeting CD24 for payload d
Slide 24: 2026 Outlook: Milestones
2026 Outlook: Milestones March 26, 2026 Pentixapharm・Fourth Quarter and FY 2025 24
Slide 25: Upcoming Clinical Milestones Poised to Drive Significant Value
Upcoming Clinical Milestones Poised to Drive Significant Value H1 2026 H2 2026 2027 2028 PANDA Phase 3 IND PANDA Phase 3 Study PANDA Phase 3 Study Cardiovascular PANDA Phase 3 Study Topline data IND FPFV First 50 patients dosed Primary expt. H2 2028 expt. H1 2026 expt. H2 2026 in U.S./EU expt. H1 20
Slide 26: Transforming Personalized Medicine: Investment Highlights
Transforming Personalized Medicine: Investment Highlights Driving Value as Advanced Clinical-Stage Company Flagship Pipeline Broadening impact of radiopharmaceuticals with Drives Near- and Long-Term Impact advanced pipeline addressing high value biology PentixaFor/Ther: Phase 3-ready diagnostic in t
Slide 27: Thank you
Thank you www.pentixapharm.com